Better research needed for formularies to focus on outcomes Newsletter Article 09 February 2013 Pages: 2 - 2
Is disease management the key to market access in Europe? Carlene Todd Newsletter Article 09 February 2013 Pages: 3 - 5
Guidelines for HIV postexposure therapy spark controversy Newsletter Article 09 February 2013 Pages: 6 - 6
Support for short-course antibacterials in URT infections Newsletter Article 09 February 2013 Pages: 6 - 6
Oral doxycycline outshines IV ceftriaxone in Lyme disease/arthritis Newsletter Article 09 February 2013 Pages: 7 - 7
Nadroparin calcium cost saving in deep vein thrombosis Newsletter Article 09 February 2013 Pages: 7 - 7
5α-reductase inhibitor not warranted for mild-to-moderate BPH symptoms Newsletter Article 09 February 2013 Pages: 8 - 8
Impact of Parkinson’s disease on society, family and patient Newsletter Article 09 February 2013 Pages: 9 - 9
Hepatic arterial infusion chemotherapy for liver metastases? Newsletter Article 09 February 2013 Pages: 9 - 9
Demand management vital for continued HMO growth in the US Newsletter Article 09 February 2013 Pages: 11 - 11
Pricing claims challenged by South African drug companies Newsletter Article 09 February 2013 Pages: 12 - 12